Panacea Biotec Share Price
Sector: Biotechnology & Drugs
412.40 +3.50 (0.86%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
408.25
Today’s High
417
52 Week Low
129.65
52 Week High
581
412.30 +4.05 (0.99%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
411.15
Today’s High
416
52 Week Low
130
52 Week High
581.90
Key Metrics
- Market Cap (In Cr) 2539.78
- Beta 0.95
- Div. Yield (%) 0
- P/B 3
- TTM P/E -
- Peg Ratio -
- Sector P/E 46.04
- D/E 0
- Open Price 408.25
- Prev Close 408.9
Panacea Biotec Analysis
Price Analysis
-
1 Week-4.01%
-
3 Months-7%
-
6 Month-9.12%
-
YTD-2.47%
-
1 Year194.38%
Risk Meter
- 59% Low risk
- 59% Moderate risk
- 59% Balanced Risk
- 59% High risk
- 59% Extreme risk
Panacea Biotec News
Hidden gems: Raja Venkatraman recommends three stocks to buy today—26 March
3 min read . 26 Mar 2025Multibagger small-cap stock hits 5% upper circuit on order win from UNICEF
1 min read . 26 Dec 2024Panacea Biotec Q1 results : loss at ₹15.8Cr, Revenue decreased by 10.43% YoY
1 min read . 16 Aug 2024Panacea Biotec Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 559.09
- Selling/ General/ Admin Expenses Total
- 173.05
- Depreciation/ Amortization
- 34.81
- Other Operating Expenses Total
- 212.41
- Total Operating Expense
- 583.82
- Operating Income
- -24.73
- Net Income Before Taxes
- -7.95
- Net Income
- -8.37
- Diluted Normalized EPS
- -5.2
- Period
- 2025
- Total Assets
- 1289.75
- Total Liabilities
- 454.96
- Total Equity
- 834.79
- Tangible Book Valueper Share Common Eq
- 129.39
- Period
- 2025
- Cashfrom Operating Activities
- -27.37
- Cashfrom Investing Activities
- 64.98
- Cashfrom Financing Activities
- -2.66
- Net Changein Cash
- 34.96
- Period
- 2024
- Total Revenue
- 559.17
- Selling/ General/ Admin Expenses Total
- 257.6
- Depreciation/ Amortization
- 36.71
- Other Operating Expenses Total
- 5.21
- Total Operating Expense
- 572.82
- Operating Income
- -13.65
- Net Income Before Taxes
- 1.48
- Net Income
- -1.17
- Diluted Normalized EPS
- -3.53
- Period
- 2024
- Total Assets
- 1240.67
- Total Liabilities
- 398.63
- Total Equity
- 842.05
- Tangible Book Valueper Share Common Eq
- 131.6
- Period
- 2024
- Cashfrom Operating Activities
- -0.1
- Cashfrom Investing Activities
- 10.23
- Cashfrom Financing Activities
- -2.81
- Net Changein Cash
- 7.32
- Period
- 2023
- Total Revenue
- 459.95
- Selling/ General/ Admin Expenses Total
- 212.51
- Depreciation/ Amortization
- 39.12
- Other Operating Expenses Total
- 2.46
- Total Operating Expense
- 465.7
- Operating Income
- -5.75
- Net Income Before Taxes
- 12.81
- Net Income
- -33.24
- Diluted Normalized EPS
- -16.5
- Period
- 2023
- Total Assets
- 1271.17
- Total Liabilities
- 427.56
- Total Equity
- 843.6
- Tangible Book Valueper Share Common Eq
- 133.49
- Period
- 2023
- Cashfrom Operating Activities
- -422.45
- Cashfrom Investing Activities
- 430.33
- Cashfrom Financing Activities
- -18.37
- Net Changein Cash
- -10.5
- Period
- 2022
- Total Revenue
- 661.23
- Selling/ General/ Admin Expenses Total
- 326.71
- Depreciation/ Amortization
- 43.66
- Other Operating Expenses Total
- 6.44
- Total Operating Expense
- -960.78
- Operating Income
- 1622.01
- Net Income Before Taxes
- 1448.81
- Net Income
- 1077.89
- Diluted Normalized EPS
- -1.82
- Period
- 2022
- Total Assets
- 1758.87
- Total Liabilities
- 882.23
- Total Equity
- 876.64
- Tangible Book Valueper Share Common Eq
- 140.87
- Period
- 2022
- Cashfrom Operating Activities
- -108.43
- Cashfrom Investing Activities
- 1282.57
- Cashfrom Financing Activities
- -1175.85
- Net Changein Cash
- -1.73
- Period
- 2021
- Total Revenue
- 624.81
- Selling/ General/ Admin Expenses Total
- 275.97
- Depreciation/ Amortization
- 45.59
- Other Operating Expenses Total
- 4.32
- Total Operating Expense
- 589.36
- Operating Income
- 35.45
- Net Income Before Taxes
- -144.25
- Net Income
- -147.7
- Diluted Normalized EPS
- -23.45
- Period
- 2021
- Total Assets
- 1177.53
- Total Liabilities
- 1406.23
- Total Equity
- -228.69
- Tangible Book Valueper Share Common Eq
- -39.82
- Period
- 2021
- Cashfrom Operating Activities
- 106.65
- Cashfrom Investing Activities
- -47.68
- Cashfrom Financing Activities
- -47.11
- Net Changein Cash
- 11.86
- Period
- 2020
- Total Revenue
- 544.06
- Selling/ General/ Admin Expenses Total
- 251.93
- Depreciation/ Amortization
- 43.22
- Other Operating Expenses Total
- 3.74
- Total Operating Expense
- 518.6
- Operating Income
- 25.46
- Net Income Before Taxes
- -171.22
- Net Income
- -194.27
- Diluted Normalized EPS
- -25.95
- Period
- 2020
- Total Assets
- 1390.3
- Total Liabilities
- 1191.51
- Total Equity
- 198.79
- Tangible Book Valueper Share Common Eq
- 29.78
- Period
- 2020
- Cashfrom Operating Activities
- -30.23
- Cashfrom Investing Activities
- -34.76
- Cashfrom Financing Activities
- 90.74
- Net Changein Cash
- 25.75
- Period
- 2019
- Total Revenue
- 456.7
- Selling/ General/ Admin Expenses Total
- 273.92
- Depreciation/ Amortization
- 54
- Other Operating Expenses Total
- 4.62
- Total Operating Expense
- 291.03
- Operating Income
- 165.67
- Net Income Before Taxes
- 48.61
- Net Income
- 37.73
- Diluted Normalized EPS
- -22.84
- Period
- 2019
- Total Assets
- 1375.52
- Total Liabilities
- 1025.12
- Total Equity
- 350.4
- Tangible Book Valueper Share Common Eq
- 54.5
- Period
- 2019
- Cashfrom Operating Activities
- 104.52
- Cashfrom Investing Activities
- -5.35
- Cashfrom Financing Activities
- -101.14
- Net Changein Cash
- -1.97
- Period
- 2025-03-31
- Total Revenue
- 132.53
- Selling/ General/ Admin Expenses Total
- 49.13
- Depreciation/ Amortization
- 8.42
- Other Operating Expenses Total
- 58.2
- Total Operating Expense
- 140.12
- Operating Income
- -7.59
- Net Income Before Taxes
- -0.04
- Net Income
- -1.89
- Diluted Normalized EPS
- -3.26
- Period
- 2025-03-31
- Total Assets
- 1289.75
- Total Liabilities
- 454.96
- Total Equity
- 834.79
- Tangible Book Valueper Share Common Eq
- 129.39
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -27.37
- Cashfrom Investing Activities
- 64.98
- Cashfrom Financing Activities
- -2.66
- Net Changein Cash
- 34.96
- Period
- 2024-12-31
- Total Revenue
- 163.49
- Selling/ General/ Admin Expenses Total
- 42.98
- Depreciation/ Amortization
- 8.98
- Other Operating Expenses Total
- 50
- Total Operating Expense
- 161.74
- Operating Income
- 1.75
- Net Income Before Taxes
- 4.38
- Net Income
- 4.52
- Diluted Normalized EPS
- 0.45
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 147.35
- Selling/ General/ Admin Expenses Total
- 43.44
- Depreciation/ Amortization
- 8.68
- Other Operating Expenses Total
- 53.72
- Total Operating Expense
- 146.26
- Operating Income
- 1.09
- Net Income Before Taxes
- 4.76
- Net Income
- 4.8
- Diluted Normalized EPS
- 0.33
- Period
- 2024-09-30
- Total Assets
- 1243.08
- Total Liabilities
- 410.17
- Total Equity
- 832.91
- Tangible Book Valueper Share Common Eq
- 130.26
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 9.62
- Cashfrom Investing Activities
- -7.85
- Cashfrom Financing Activities
- -1.27
- Net Changein Cash
- 0.5
- Period
- 2024-06-30
- Total Revenue
- 115.72
- Selling/ General/ Admin Expenses Total
- 37.5
- Depreciation/ Amortization
- 8.73
- Other Operating Expenses Total
- 50.49
- Total Operating Expense
- 135.7
- Operating Income
- -19.98
- Net Income Before Taxes
- -17.05
- Net Income
- -15.8
- Diluted Normalized EPS
- -2.88
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 136.46
- Selling/ General/ Admin Expenses Total
- 38.43
- Depreciation/ Amortization
- 8.81
- Other Operating Expenses Total
- 54.32
- Total Operating Expense
- 148.57
- Operating Income
- -12.11
- Net Income Before Taxes
- -2.12
- Net Income
- -1.66
- Diluted Normalized EPS
- -0.56
- Period
- 2024-03-31
- Total Assets
- 1240.67
- Total Liabilities
- 398.63
- Total Equity
- 842.05
- Tangible Book Valueper Share Common Eq
- 131.6
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -0.1
- Cashfrom Investing Activities
- 10.23
- Cashfrom Financing Activities
- -2.81
- Net Changein Cash
- 7.32
- Period
- 2023-12-31
- Total Revenue
- 150.5
- Selling/ General/ Admin Expenses Total
- 37.65
- Depreciation/ Amortization
- 9.11
- Other Operating Expenses Total
- 45.68
- Total Operating Expense
- 156.98
- Operating Income
- -6.48
- Net Income Before Taxes
- -1.65
- Net Income
- -2.2
- Diluted Normalized EPS
- -0.67
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Panacea Biotec Technical
Moving Average
SMA
- 5 Day420.87
- 10 Day432.39
- 20 Day454.33
- 50 Day496.31
- 100 Day439.65
- 300 Day404.6
Panacea Biotec Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Indoco Remedies
- 295.05
- 0.45
- 0.15
- 385.5
- 190
- 2717.12
- Gujarat Themis Biosyn
- 344.25
- -1.4
- -0.41
- 390
- 192.35
- 3781.39
- Panacea Biotec
- 412.4
- 3.5
- 0.86
- 581
- 129.65
- 2539.78
- Novartis India
- 1009.95
- -0.9
- -0.09
- 1248
- 744.95
- 2493.65
- Sms Pharmaceuticals
- 250.1
- 3.35
- 1.36
- 398
- 175
- 2213.49
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Indoco Remedies
- -
- 2.63
- 8.9
- 5.16
- Gujarat Themis Biosyn
- 76.77
- 15.09
- 35.83
- 35.51
- Panacea Biotec
- -
- 3.11
- 31.18
- 30.99
- Novartis India
- 24.99
- 3.21
- 8.34
- 16.56
- Sms Pharmaceuticals
- 29.3
- 3.31
- 9.98
- 8.05
Panacea Biotec Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-May-25
- Audited Results & Dividend
- 14-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 14-Aug-24
- Quarterly Results
- 30-May-24
- Audited Results
- 13-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results
- 14-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 31-Mar-25
- 27-Feb-25
- POM
- 28-Dec-24
- 26-Nov-24
- POM
- 27-Sept-24
- 16-Sept-24
- AGM
- 13-Apr-24
- 12-Mar-24
- POM
- 29-Sept-23
- 14-Aug-23
- AGM
- 28-Jun-22
- 27-May-22
- POM
- 26-Feb-22
- 01-Feb-22
- EGM
- 25-Sept-21
- 23-Jul-21
- AGM
- 25-Jun-21
- 02-Jun-21
- EGM



